You searched for: plasminogen (Engelska - Maltesiska)

tenecteplase is a recombinant fibrin-specific plasminogen activator.
tenecteplase hu attivatur rikombinanti ta’ plasminogen li hu speċifiku għal fibrin.

reteplase 10 u (recombinant plasminogen activator, thrombolytic agent)
reteplase 10 u (attivatur rikombinanti ta’ plażminoġen, aġent trombolitiku)

tenecteplase is an intravenously administered, recombinant protein that activates plasminogen.
tenecteplase hu proteina rikombinanti li tingħata ġol-vina li tattiva l-plasminogen.

** recombinant plasminogen activator produced in escherichia coli by recombinant dna technology.
** attivatur rikombinanti ta ’ plasminogen prodott f’ echerichia coli permezz ta ’ teknoloġija ta ’ dna rikombinata.

rapilysin contains the active substance reteplase(a recombinant plasminogen activator).
rapilysin fiha is-sustanza attiva reteplase (attivatur rikombinanti ta’ plażminoġen).

reductions of plasma levels of plasminogen and 2-antiplasmin normalise within 1 to 3 days.
tnaqqis fil-livelli tal-plażma tal-plasminogen u ta’ l-2-antiplasmin jinnormalizzaw fi żmien 1 sa 3 t’ijiem.

reteplase is a recombinant plasminogen activator that catalyzes the cleavage of endogenous plasminogen to generate plasmin.
reteplase huwa attivatur rikombinanti tal-plażminoġen li jikkatalizza l-qtugħ (dak li jkisser il- molekula) endoġeniku tal-plażminoġen biex jipproduċi l-plażmin.

tenecteplase is a fibrin-specific plasminogen activator produced in a chinese hamster ovary cell line by recombinant dna technology.
tenecteplase hu attivatur ta’ plasminogen li hu speċifiku għal fibrin prodott minn razza ta’ ċelluli fl-ovarji tal-ħamster Ċiniż permezz tat-teknoloġija rikombinanti tad-dna.

if you are receiving tissue type plasminogen activator as acute treatment for blood clots, you should not be treated with ruconest at the same time.
jekk qiegħed/qiegħda tirċievi attivatur tal-plasminoġen tip ta’ tessut bħala kura akuta għal emboli tad- demm, inti ma għandekx tiġi kkurat/a b’ruconest fl-istess ħin.

as with other plasminogen activators a rebound phenomenon then occurs during which fibrinogen levels reach a maximum within 9 days and remain elevated for up to 18 days.
bħall-attivaturi oħra tal- plasminogen, il-fenomenu ta’ ‘rebound’ imbagħad isseħħ waqt li l-livelli tal-fibrinogen jilħqu massimu fi żmien 9 t’ijiem u jibqgħu għoljin sa 18-il jum.

it works by converting a protein in the clots called plasminogen into its active form, plasmin, which breaks down the fibrous protein holding the clot together.
jaħdem billi jikkonverti proteina fl-emboli msejħa plasiminogen fil-forma attiva tagħha, plasmin, li tkisser il-proteina fibruża li żżomm l-embolu magħqud.

in any case, tenecteplase should not be re- administered before assessment of haemostatic factors like fibrinogen, plasminogen and alpha2- antiplasmin.
fi kwalunkwe każ, tenecteplase m’għandux jingħata mill-ġdid qabel evalwazzjoni ta’ fatturi emostatiċi bħal fibrinogen, plasminogen u alpha2-antiplasmin.

xigris also restored endogenous fibrinolytic potential, as evidenced by a more rapid trend toward normalisation in plasminogen levels and a more rapid decline in plasminogen activator inhibitor-1 levels.
xigris radd lura wkoll il-potenzjal fibrinolitiku endoġenu, kif jidher minn tendenza aktar mgħaġġla lejn in-normalizzazzjoni fil-livelli tal-plażminoġen u tnaqqis aktar mgħaġġel fil-livelli ta’ l-inibitur-1 ta’ l-attivatur tal-plażminoġen.

plasminogen activator inhibitor 1 (pai-1) activity can be reduced to around zero, but rapidly normalises within two hours showing a rebound phenomenon.
l- attività ta’ l-inibitur ta’ l-attivatur tal-plasminoġen 1 (pai-1) tista’ tkun imnaqqsa għal madwar żero, iżda tinnormalizza malajr fi żmien sagħtejn, filwaqt li turi l-fenomenu ta’ rebound’.

the active substance in metalyse, tenecteplase, is a modified copy of the human enzyme ‘tissue plasminogen activator’, which the body uses to break down clots.
is-sustanza attiva f’metalyse, tenecteplase, hija kopja modifikata tal-enzima tal-bniedem ‘attivatur tal- plasminogen tal-bniedem’, li l-ġisem juża biex ikisser l-emboli tad-demm.

it binds to the fibrin component of the thrombus (blood clot) and selectively converts thrombus-bound plasminogen to plasmin, which degrades the fibrin matrix of the thrombus.
hu jeħel mal-komponent tal- fibrin tat-trombus (embolu tad-demm) u jibdel b’mod selettiv il-plasminogen li jkun imwaħħal ma’ l- embolu għal plasmin, li jiddegrada l-matriċi tal-fibrin ta’ l-embolu.

also, in vitro, defibrotide has been shown to increase tissue-type plasminogen activator (t-pa) function and decrease plasminogen activator inhibitor-1 (pai-1) activity resulting in a decrease in procoagulant activity and an increase in the fibrinolytic potential of endothelial cells.
barra minn hekk, defibrotide intwera li jżid il-funzjoni tal-attivatur tal-plasminoġen tat-tip tat-tessut (t- pa) u jnaqqas l-attività tal-inibitur-1 tal-attivatur tal-plasminogen (pai-1) u dan jirriżulta fi tnaqqis fl- attività prokoagulanti u f'żieda fil-potenzjal fibrinolitika taċ-ċelloli endoteljali.